X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs UNICHEM LAB - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. UNICHEM LAB FRESENIUS KABI ONCO./
UNICHEM LAB
 
P/E (TTM) x 22.1 -64.6 - View Chart
P/BV x 3.1 0.7 430.8% View Chart
Dividend Yield % 0.0 2.3 -  

Financials

 FRESENIUS KABI ONCO.   UNICHEM LAB
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
UNICHEM LAB
Mar-18
FRESENIUS KABI ONCO./
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs176382 46.1%   
Low Rs79234 33.5%   
Sales per share (Unadj.) Rs37.7116.3 32.4%  
Earnings per share (Unadj.) Rs5.1-18.9 -26.9%  
Cash flow per share (Unadj.) Rs6.7-11.7 -57.3%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.6 0.0%  
Book value per share (Unadj.) Rs42.5381.0 11.2%  
Shares outstanding (eoy) m158.2370.34 225.0%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.42.6 127.5%   
Avg P/E ratio x25.0-16.3 -153.5%  
P/CF ratio (eoy) x18.9-26.2 -72.1%  
Price / Book Value ratio x3.00.8 369.9%  
Dividend payout %0-26.4 0.0%   
Avg Mkt Cap Rs m20,13521,668 92.9%   
No. of employees `0001.22.3 50.5%   
Total wages/salary Rs m7032,006 35.0%   
Avg. sales/employee Rs Th5,176.23,587.8 144.3%   
Avg. wages/employee Rs Th610.4880.0 69.4%   
Avg. net profit/employee Rs Th699.6-583.7 -119.8%   
INCOME DATA
Net Sales Rs m5,9638,180 72.9%  
Other income Rs m18610 3.0%   
Total revenues Rs m5,9818,790 68.0%   
Gross profit Rs m1,430-1,320 -108.3%  
Depreciation Rs m258505 51.1%   
Interest Rs m-2680 -32.5%   
Profit before tax Rs m1,216-1,295 -93.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34233 1,023.9%   
Profit after tax Rs m806-1,331 -60.6%  
Gross profit margin %24.0-16.1 -148.6%  
Effective tax rate %28.1-2.6 -1,090.5%   
Net profit margin %13.5-16.3 -83.1%  
BALANCE SHEET DATA
Current assets Rs m5,10223,318 21.9%   
Current liabilities Rs m2,3854,635 51.5%   
Net working cap to sales %45.6228.4 19.9%  
Current ratio x2.15.0 42.5%  
Inventory Days Days150122 123.2%  
Debtors Days Days113121 93.3%  
Net fixed assets Rs m5,1488,163 63.1%   
Share capital Rs m158141 112.4%   
"Free" reserves Rs m6,55626,660 24.6%   
Net worth Rs m6,73226,801 25.1%   
Long term debt Rs m9523 28,854.5%   
Total assets Rs m10,38831,890 32.6%  
Interest coverage x-45.8-15.2 301.7%   
Debt to equity ratio x0.10 114,876.4%  
Sales to assets ratio x0.60.3 223.8%   
Return on assets %7.5-3.9 -191.4%  
Return on equity %12.0-5.0 -241.1%  
Return on capital %14.6-4.5 -321.5%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2984,356 121.6%   
Fx outflow Rs m1,7720-   
Net fx Rs m3,5254,356 80.9%   
CASH FLOW
From Operations Rs m1,274-1,123 -113.4%  
From Investments Rs m-1,20416,487 -7.3%  
From Financial Activity Rs m-196-8,811 2.2%  
Net Cashflow Rs m-1266,552 -1.9%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 15.1 2.0%  
FIIs % 9.6 3.0 320.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 31.7 28.7%  
Shareholders   42,599 20,176 211.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ALEMBIC PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS